044 209 91 25 079 869 90 44
Merkliste
Die Merkliste ist leer.
Der Warenkorb ist leer.
Kostenloser Versand möglich
Kostenloser Versand möglich
Bitte warten - die Druckansicht der Seite wird vorbereitet.
Der Druckdialog öffnet sich, sobald die Seite vollständig geladen wurde.
Sollte die Druckvorschau unvollständig sein, bitte schliessen und "Erneut drucken" wählen.

Kidney Cancer

BuchGebunden
Verkaufsrang122048inMedizin
CHF202.00

Beschreibung

Kidney cancer is a heterogenous disease. This book covers:
-new surgical approaches which are becoming the standard, i.e., nephon sparing, laporascopic, minimally invasive techniques;
-new staging and prognostic capabilities;
-evolving therapeutic options include, cell based vaccine, gene and antibody therapy;
-molecular genetics allow for a better understanding of the various types of kidney cancer.
Kidney Cancer is a comprehensive review covering present and future surgical approaches, staging and prognostic factors, currently accepted and future plans for prevention, diagnosis and treatment. Contributing authors to this book are internationally recognized specialists in this disease. This book will be useful to the specialist (oncologist and urologist), primary care physicians, patients and family members dealing with kidney cancer.
Weitere Beschreibungen

Details

ISBN/GTIN978-1-4020-7457-8
ProduktartBuch
EinbandGebunden
Erscheinungsdatum31.10.2003
Reihen-Nr.116
Seiten246 Seiten
SpracheEnglisch
MasseBreite 155 mm, Höhe 235 mm
Gewicht1200 g
Artikel-Nr.3275797
KatalogBuchzentrum
Datenquelle-Nr.1707515
WarengruppeMedizin
Weitere Details

Reihe

Über den/die AutorIn

Robert A. Figlin, Professor of Medicine, Urology, Departments of Medicine and Urology, Division of Hematology/Oncology, University of California, Los Angeles School of Medicine, USA, holds the Henry Alvin and Carrie L. Meinhardt Chair in Urologic Oncology. He serves as Medical Director of the Thoracic and Genitourinary Oncology Program. He is a Senior Clinical Investigator in areas of genitourinary and thoracic oncology and has served as Principal Investigator on Phase I, II, and III trials. He serves as Chairman of the UCLA Medical Institutional Review Board and as a member of the UCLA Human Research Policy Board.